Mary Donohue, MS

Senior Director, Clinical Development Clinical Operations
Biohaven Pharmaceuticals, Inc.

Poster(s):

• 110: Phase 1, Single-Center, Randomized, Placebo-Controlled, Partially Blinded, Single Ascending Dose Study on the Effects of Troriluzole on corrected QT in Healthy Subjects
  Monday, September 9, 2024

  5:00 PM – 7:00 PM ET